Showing 11-20 of 2969 results for "".
DermWireTV: AcneAlly Launches, Rosacea Insights, MC2/EPI Collaboration
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-acneally-launches-rosacea-insights-mc2epi-collaboration/19849/Dennis Porto, MD and Riyaz Farhaad, MD have launched AcneAlly.com, an online service that allows patients access to a board certified dermatologist and a standardized approach to assessment and long-term monitoring. Julie Harper, MD discusses findings from “Beyond the visible: Rosacea and psoriasis- Cutera Hosts AviClear Webinar This Weekhttps://practicaldermatology.com/news/cutera-hosts-aviclear-webinar-this-week/2461178/Cutera hosts the first webinar for AviClear, the first and only FDA cleared energy-based device for the treatment of mild, moderate, and severe acne, this week. Dermatologists Jeffrey S. Dover, MD, FRCPC and Julie C. Harper, MD will discuss the latest advancement in the treatment of acne and share…
- Actress Cynthia Nixon Helps Americans to Come Face to Face with Rosaceahttps://practicaldermatology.com/news/20121014-actress_cynthia_nixon_wants_americans_to_come_face_to_face_with_rosacea/2459707/Some of the 16 million Americans affected by rosacea are not seeking therapy, but a new initiative encourages them to come "Face to Face" with the disease. Supported by Galderma in association with the National Rosacea Society National Rosacea Society, the "Face to Face with Rosacea Symposium" brou…
- Rosacea Awareness Month Brings Focus to Common Skin Diseasehttps://practicaldermatology.com/news/rosacea-awareness-month-brings-focus-to-common-skin-disease/2460342/It’s Rosacea Awareness Month, and the National Rosacea Society (NRS) continues to educate the public on this potentially serious condition estimated to affect more than 16 million Americans. “Although the occurrence of rosacea has been well documented over the centuries, virtually everything we no…
- Sun Pharma’s WINLEVI for Acne Now Availablehttps://practicaldermatology.com/news/sun-pharmas-winlevi-for-acne-now-available/2460974/WINLEVI (clascoterone) cream 1% is now available the US, according to Sun Pharmaceutical Industries Limited. A first-in-class topical androgen receptor inhibitor, WINLEVI was approved by FDA in August 2020 for the topical treatment of acne vulgaris in patients 12 years of age and older. It is the …
- Experts Call for Greater Attention to Persistent Redness of Rosaceahttps://practicaldermatology.com/news/experts-call-for-greater-attention-to-persistent-redness-of-rosacea/2460896/Dermatologists should place greater emphasis on persistent facial erythema of rosacea, a panel of experts concludes. Their recommendations, based on a National Rosacea Society (NRS) roundtable conversation, appear in the Journal of Drugs in Dermatology. “Based on current scientific knowledge and cl…
- AARS Survey Uncovers Real Impact Of Acne On Young Professionalshttps://practicaldermatology.com/news/aars-survey-uncovers-real-impact-of-acne-on-young-professionals/2460087/Results of a recent American Acne and Rosacea Society (AARS) survey highlight the significant health burden and everyday impact of acne on young professionals. According to the survey of 1,004 men and women between the ages of 22 and 30 conducted by The Harris Poll, many people whose acne persists …
- New Patient-Centered Panel Helps BioPharmX Define its Role in the Future of Dermatologyhttps://practicaldermatology.com/news/new-patient-centered-panel-helps-biopharmx-define-its-role-in-the-future-of-dermatology/2457721/BioPharmX Corporation has formed a Special Advisory Council of thought leaders from various disciplines to help the company embrace patient centricity in its products, pricing, and market access considerations. The advisors, who bring decades of experience in fields beyond dermatology—ranging from…
- NEA Announces 2022 Research Grant Recipientshttps://practicaldermatology.com/news/nea-announces-2022-research-grant-recipients/2461457/The National Eczema Association (NEA) announced the recipients for its 2022 research grants. From both U.S.-based and international applications, the research projects of 13 investigators were selected, representing grants totaling nearly $730,000. 2022 marked a significant jump in NEA's investmen…
- Galderma and Aklief Unveil "Me Being Me" Campaign, Survey Results on Acne Zoom Burdenhttps://practicaldermatology.com/news/galderma-and-aklief-unveil-me-being-me-campaign-survey-results-on-acne-zoom-burden/2460703/Galderma Laboratories, L.P. and Aklief (trifarotene) Cream, 0.005% are launching Me Being Me, a new consumer campaign that was crafted in response to today’s increasingly digital-focused world. The campaign is designed to inspire those living with acne to feel confident in their own skin by sharin…